Based upon the success of anti-neoplastic treatment in pediatric oncology, the detection, treatment and avoidance of late effects and the improvement of the after-care has become increasingly important. In 1995, the Late Effects Surveillance System (LESS) in the network of the Society for Pediatric Oncology and Hematology [Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)] started to register late effects in patients treated according the therapy-optimized studies of the GPOH. More than 2,500 former Ewing-, osteo- and soft tissue sarcoma patients are currently being investigated prospectively according to the follow-up guidelines of the GPOH. The most notable late effects for cancer therapy are anthracycline-induced cardiomyopathy, hearing loss and nephrotoxicity after cisplatin, ifosfamide-induced tubulopathy, as well as developmental and other endocrinological disturbances, e.g. fertility loss and dysfunction of the thyroid. New knowledge on structured aftercare is fundamental to a vertical network between physicians in hospitals and in practices for the care of children and adolescents formerly suffering from cancer.
|Translated title of the contribution||Detection, avoidance and treatment of late effects in the follow-up of children and adolescents with cancer|
|Number of pages||9|
|Publication status||Published - 10.2005|
Research Areas and Centers
- Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)